High-Dose lnterleukin-2 Remains Effective as First-Line Therapy for Metastatic Renal Cell Carcinoma
The point here is that Interleukin 2 came out in the 90’s with responses seen in kidney cancer, a notoriously difficult to treat can but IL2 was considered extremely toxic. So researchers, statistician and clinicians looked at the data of the right group types of kidney cancer patients and found not only were there durable responses and high response rates- they went back to the 90’s and saw people still alive and in high numbers who received and survived Il2 . The package insert was not reflective of 25 years of looking back
November 7, 2015—Miami, Florida—High-dose interleukin-2 has been shown to offer a favorable safety profile compared to data in the original package insert and remains an effective first line therapy for eligible patients with metastatic renal cell carcinoma.
This conclusion, drawn from results of a survival analysis of a registry including retrospective and prospective patient cohorts, was reported at the 14th Annual International Kidney Cancer Symposium, from November 6 – 7.
The data support the favorable safety profile of high-dose interleukin-2 compared to the original package insert. High-dose interleukin-2 remains an effective first-line therapy for eligible patients with metastatic renal cell carcinoma.
Sandra Aung, PhD, of Prometheus Laboratories, Inc., said, “Modern experience with interleukin-2 suggests it is a first-line option in eligible patients. Interleukin-2 offers a favorable safety profile, unlike that described in the package insert, which is over 20 years old.”